Company Overview
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Why Investors Should Care
Net profit has compounded at 41.0% per year over the last five years.
Trades at a P/E of 19.0, below the sector median of 24.8.
Offers a dividend yield of 2.88%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $6.16B (+6.1% YoY); net profit $625.00M.
- Trailing 12 Months Year-on-year growth — revenue +4.6%, earnings +5.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.7%, profit CAGR 41.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.73% |
| 1 Year: | 4.60% |
Compounded Profit Growth
| 5 Years: | 40.99% |
| 1 Year: | 5.70% |
Stock Price Performance
| 1 Year: | -22.44% |
| 6 Months: | -16.98% |
| 3 Months: | -8.14% |
| 1 Month: | -7.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.46 · Neutral
P/E of 18.96 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 41.0% over 5 years.
- Attractive dividend yield of 2.88%.
- Generates positive free cash flow.
CONS
- Trading 26.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SNN Smith & Nephew plc PHARMA | 27.87 | 18.96 | $11.66B | 2.88% | 9.67% | 11.85% | 5.73% | 40.99% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 5.21B | 5.55B | 5.81B | 6.16B |
| Cost of Revenue | - | 1.54B | 1.73B | 1.76B | 1.97B |
| Gross Profit | - | 3.67B | 3.82B | 4.05B | 4.19B |
| Operating Expenses | - | 3.04B | 3.20B | 3.19B | 3.33B |
| Operating Income | - | 634.00M | 620.00M | 860.00M | 857.00M |
| EBITDA | - | 874.00M | 956.00M | 1.22B | 1.53B |
| Interest Expense | - | 91.00M | 139.00M | 168.00M | 179.00M |
| Pretax Income | - | 235.00M | 290.00M | 498.00M | 779.00M |
| Tax Provision | - | 12.00M | 27.00M | 86.00M | 154.00M |
| Net Income | - | 223.00M | 263.00M | 412.00M | 625.00M |
| Diluted EPS | - | 0.50 | 0.60 | 0.94 | 1.43 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 9.97B | 9.99B | 10.35B | 10.46B |
| Current Assets | - | 3.86B | 4.03B | 4.42B | 4.10B |
| Cash & Equivalents | - | 350.00M | 302.00M | 619.00M | 557.00M |
| Inventory | - | 2.21B | 2.40B | 2.39B | 2.12B |
| Receivables | - | 1.03B | 1.06B | 1.06B | 1.16B |
| Total Liabilities | - | 4.71B | 4.77B | 5.09B | 5.17B |
| Current Liabilities | - | 1.72B | 2.27B | 1.53B | 1.59B |
| Long Term Debt | - | 2.56B | 2.17B | 3.12B | 3.03B |
| Total Debt | - | 2.87B | 3.08B | 3.32B | 3.33B |
| Total Equity | - | 5.26B | 5.22B | 5.26B | 5.29B |
| Shares Outstanding | - | 877.65M | 877.67M | 877.70M | 877.72M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 468.00M | 608.00M | 987.00M | 1.28B |
| Investing Cash Flow | - | -472.00M | -448.00M | -569.00M | -406.00M |
| Financing Cash Flow | - | -926.00M | -200.00M | -86.00M | -955.00M |
| Capital Expenditure | - | -358.00M | -427.00M | -381.00M | -433.00M |
| Free Cash Flow | - | 110.00M | 181.00M | 606.00M | 852.00M |
| Net Change in Cash | - | -930.00M | -40.00M | 332.00M | -76.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 70.5% | 68.8% | 69.6% | 68.0% |
| Operating Margin % | - | 12.2% | 11.2% | 14.8% | 13.9% |
| Net Margin % | - | 4.3% | 4.7% | 7.1% | 10.1% |
| ROE % | - | 4.2% | 5.0% | 7.8% | 11.8% |
| ROCE % | - | 7.7% | 8.0% | 9.7% | 9.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | River Road Asset Management, LLC | 0.77% | 3.22M | $88.79M |
| 2 | Goldman Sachs Group Inc | 0.73% | 3.07M | $84.60M |
| 3 | Brandes Investment Partners L.P. | 0.51% | 2.15M | $59.22M |
| 4 | Dimensional Fund Advisors LP | 0.44% | 1.84M | $50.63M |
| 5 | LMR Partners LLP | 0.42% | 1.77M | $48.72M |
| 6 | Causeway Capital Management LLC | 0.37% | 1.57M | $43.14M |
| 7 | Wells Fargo & Company | 0.33% | 1.38M | $37.91M |
| 8 | Todd Asset Management LLC | 0.30% | 1.25M | $34.50M |
| 9 | Morgan Stanley | 0.29% | 1.20M | $33.19M |
| 10 | Bank of Montreal /CAN/ | 0.27% | 1.15M | $31.56M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SNN
S.N. Nuclearelectrica (BVB:SNN) Stock Sees Fair Value Cut As Analysts Turn More Cautious - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPeUoxbFNhNnlfdkh6TFc5ZGUxbFpUTFVQSFRQYzl4M1FSQXpYX1dhMWxKME9UcWY3Ul9oSDBjN25qT2ZZRWExZW1PeEFTOXU2VnYwbkRVRDZtclRPSERtZ1Rrc2liVTBBT3k0RUtzbEN2QkEtM2JVZUhiZHF3T0sxcWVMSlBRY1E5R1VwaG…
MRK Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTFA4WjVRVFNCUXZaSGtKVkd5dTlHNXVvLXBzWTRPZy11N3VsUTRVMHpXakxlSlpCNnZhekxJT2FDSVFyTklCODYyMkN0UHRkRjQ?oc=5" target="_blank">MRK Stock Quote Price and Forecast</a> <font colo…
MU Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE12OGhUSWtGTk9iWTJqbXhwZ2hpa25tNUxnRWlMam1RYkNBckpUdlVCMXgzY2ZDbG1HUkdxeFlUMWRkZ3ljR2xXUkdJb285UQ?oc=5" target="_blank">MU Stock Quote Price and Forecast</a> <font color=…
Orthopaedics chief at Smith & Nephew (NYSE: SNN) granted new share awards - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPTllSN3Z2aU9ZSktxNElPczFRZ1Y3RHNyVmR5ckk3dENpbHA3QTBpOHhlRzdhMlhpQlhOblNKT3lqVXM2VDRfLWRnOUR5SkhJLW1lTXZDTlY0TUNYOFJJRUpIWWNMOHhEQ3hjNVMzeWRGNmNEZkxpcWpSYXFDZVFPemF4OHlWYl82dDRvUl…
Disappointing Ortho Performance Continues To Hold Smith & Nephew Back (Downgrade) (SNN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOZEpMdTRQcXl5UnRnZFN6a1JxNDRiNVVQaW56U1NrQ2NRS3BiQjlQUTF1a29zSGNOSFlSNXFBR3ZUSFZRMVFyLWdPTUVaRlc2LUR6R2l4OHIySm9fcGlMTWRDZU53MGhhU3BteFdPVkZfN2dhd1hUSkVlYjhHRlM5MVFwS0VOdDA4Y0lvX2…
Smith & Nephew SNATS, Inc. (SNN) Stock Analysis: Exploring A 16.20% Potential Upside - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxON09PWS0zaVViTXRYbTI4bUR3QnMwY1VOLWdXcWNGcjFENnc3ZnAyMWdzVmJ6QzMydkhPMGc0LXRHN3Bvek82VGVldThIZjdqM21BNmpJQmhQcWpxeU5zdTZyVHZ1d0xZWmVOUXdEN2FVaG5NTWFBS2VrMzFXeEI4QkF0aVRidmgwT2ZiZE…
SNN — Frequently Asked Questions
What is the current share price of Smith & Nephew plc (SNN)?
As of 2026-09-19 21:16 PDT, Smith & Nephew plc (SNN) trades at $27.87 on NYSE. Its 52-week range is $27.87 to $37.81.
What is the market capitalisation of SNN?
Smith & Nephew plc (SNN) has a market capitalisation of $11.66B on NYSE.
What is the P/E ratio of SNN?
SNN trades at a trailing price-to-earnings (P/E) ratio of 18.96. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 11.32.
Does SNN pay a dividend?
Smith & Nephew plc (SNN) currently offers a dividend yield of 2.88%.
What is the return on equity (ROE) of SNN?
SNN has a return on equity (ROE) of 11.85%. Its return on capital employed (ROCE) is 9.67%.
Is SNN a good stock to buy?
This page provides a data-driven analysis of Smith & Nephew plc (SNN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.